Corgenix Med Corp (CONX) 0.4610 $CONX
Corgenix Rapid Diagnostic Ebola Test Research Earns Divisional Best Abstract Award at AACC 2014 Meeting
Business Wire - Wed Jul 30, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX) has been recognized for outstanding research presented today at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago. Corgenix earned the award for its poster abstract "Development of a Point-of-Care Diagnostic for Ebola and Sudan Virus Detection," presented at the conference by Corgenix Research Associate Abby Jones, M.S.
Corgenix Joins Strategic Partners, Presents Science at AACC Meeting and Clinical Lab Expo 2014
Business Wire - Tue Jul 22, 8:15AM CDT
Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, will collaborate with strategic partners and also present several scientific abstracts at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago.
Corgenix enters into technology transfer & product development agreement for Mellitussfor gestational diabetes test GCD59
M2 - Tue Jul 15, 8:29AM CDT
Diagnostic test kits company Corgenix Medical (Other OTC:CONX) on Monday launched a technology transfer and product development agreement with Mellitus in support of clinical research and product commercialisation.
Corgenix Signs Technology Transfer, Product Development Agreement with Mellitus LLC for Gestational Diabetes Test
Business Wire - Mon Jul 14, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today announced a technology transfer and product development agreement with Mellitus LLC of Cambridge, Mass. Mellitus is a private company that is developing a novel in vitro diagnostic test with potential clinical utility for diabetes. The test is based on the measurement of Glycated CD59 (GCD59.)
Corgenix, Research Group Announce NIH Grant to Advance Work on Ebola Rapid Diagnostic Test Kit
Business Wire - Thu Jun 26, 8:15AM CDT
Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, has been awarded a three-year, $2.9 million National Institutes of Health (NIH) grant to advance the development of an Ebola rapid diagnostic test kit. Collaborating with Corgenix on the program will be members of the Viral Hemorrhagic Fever Consortium (VHFC), a collaboration of academic and industry members headed by Tulane University and partially funded with support from the NIH.
Corgenix, Tulane and Viral Hemorrhagic Fever Consortium Publish Promising Results from Lassa Fever Trial
Business Wire - Tue Apr 01, 8:15AM CDT
A Corgenix Medical (OTCBB:CONX) rapid diagnostic test (RDT) for the dangerous Lassa fever virus has demonstrated the ability to quickly detect the virus, responsible for the deaths of thousands and infection of hundreds of thousands in West Africa each year. That's according to the results of the five-year trial Lassa Fever in Post-Conflict Sierra Leone published in the PLOS Neglected Tropical Diseases Journal.
Corgenix and Research Partners to Expand Ebola Virus Testing Capabilities in Sierra Leone
Business Wire - Thu Mar 27, 8:15AM CDT
An outbreak of the deadly Ebola virus in West Africa has prompted Corgenix Medical Corporation (OTCBB:CONX) to extend its existing viral hemorrhagic fever (VHF) rapid test development to include the Ebola virus. Corgenix has already developed and CE marked a rapid test for the Lassa fever virus, another member of the VHF group of viruses.
Corgenix Board of Directors Announces Exploration of Strategic Alternatives
Business Wire - Wed Mar 12, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that the Company's Board of Directors has decided to explore strategic alternatives to enhance value for shareholders. These alternatives could include, among others, possible joint ventures, strategic partnerships or alliances, a sale of the Company or other possible transactions.
Corgenix Medical Corporation posts higher net income of USD178,497 for Q2 fiscal 2014
M2 - Fri Feb 14, 3:06AM CST
Diagnostic test kits company Corgenix Medical Corporation (OTC BB:CONX) reported on Thursday its net income of USD178,497 for second quarter fiscal 2014.
Corgenix Reports Second Quarter Fiscal 2014 Financial Results
Business Wire - Thu Feb 13, 8:15AM CST
Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its second quarter Form 10-Q and reported its financial results. The report disclosed that the company's revenues and net income increased both for the quarter and year to date. Some of the results highlighted by the report are as follows:
Corgenix to Host Conference Call to Discuss Second Quarter Results
Business Wire - Tue Feb 04, 8:15AM CST
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, February 13, 2014, at 4:00 p.m. EST to discuss the Company's financial and operating performance for its quarter ended December 31, 2013, and the status of the Company's product development and marketing activities.
Corgenix Announces Filing of 510(k) Premarket Notification for FDA Clearance of TxBCardio(TM) Assay
Business Wire - Mon Dec 16, 8:15AM CST
Corgenix Medical Corporation (OTC BB: CONX.OB) announced today that in collaboration with Randox Laboratories, the first premarket notification has been filed with the U.S. Food and Drug Administration pursuant to Section 510(k) of the U.S. Federal Food, Drug and Cosmetic Act for the TxBCardio(TM) immunoturbidimetric (IT) assay.
Corgenix to Host Conference Call to Discuss Fiscal 2013 Results
Business Wire - Wed Sep 18, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Monday, September 30, 2013, at 4:00 PM EDT to discuss the Company's financial and operating performance for its fiscal year ended June 30, 2013, and the status of the Company's product development and marketing activities.
Corgenix Medical Corporation renews agreement with Dr Matsuura and retains right to the AtherOx technology
M2 - Wed Sep 11, 9:38AM CDT
Diagnostic kits company Corgenix Medical Corporation (OTCQB:CONX.OB) reported on Tuesday the execution of a new AtherOx License and Cooperation Agreement with Dr Eiji Matsuura of Okayama, Japan.
Corgenix Medical Corporation Announces New AtherOx(R) (Oxidized LDL Technology) License and Cooperation Agreement
Business Wire - Tue Sep 10, 8:15AM CDT
Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced signing of a new AtherOx(R) License and Cooperation Agreement with Eiji Matsuura, Ph.D., an individual of Okayama, Japan. Concurrently with the execution of the new agreement, Dr. Matsuura terminated his arbitration demand of June 28, 2013 related to the April 14, 2010 Amended and Restated License Agreement between the parties.
Corgenix Medical Corporation reports new USD1.5m revolving credit facility, with favorable interest rate and greater flexibility
M2 - Thu Sep 05, 6:29AM CDT
Diagnostic test kits company Corgenix Medical Corporation (OTCQB:CONX.OB) revealed on Wednesday the completion of a USD1.5m secured revolving line of credit with Bank of the West.
Corgenix Medical Corporation Announces New $1.5 Million Revolving Credit Facility
Business Wire - Wed Sep 04, 8:15AM CDT
Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced that it has closed on a $1.5 million secured revolving line of credit with Bank of the West. The new revolving line of credit provides Corgenix a very favorable interest rate and much greater flexibility than the previous asset-based revolving line of credit. The new credit facility follows the recent move by Corgenix of its primary banking arrangements to Bank of the West.
OTC Daily Alert Stock Watch - Corgenix (OTCQB: CONX)
WorldStockWire - Tue Aug 27, 7:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Global Personalized Medicine Diagnostics Market 2012-2016: AltheaDx Inc. Launches FLT3 Mutation Assay in October 2012
M2 - Tue Aug 06, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/x63hs3/global) has announced the addition of the "Global Personalized Medicine Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Personalized Medicine Diagnostics market to grow at a CAGR of 4.43 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for personalized medicine for treating cancer. The Global Personalized Medicine Diagnostics market has also been witnessing an increase in the number of industrial activities. However, the low awareness of personalized medicine diagnostics in developing countries could pose a challenge to the growth of this market. The key vendors dominating this space include Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, bioMerieux SA, Illumina Inc., and Roche Holding AG. Commenting on the report, an analyst from the team said: One of the main trends witnessed in the Global Personalized Medicine Diagnostics market is the development of innovative tools and technologies. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Furthermore, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 to predict the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. According to the report, one of the main factors driving the market is the increasing demand for personalized medicine diagnostics for treatment of cancer. Hyperthermia is one of the treatments of cancer where the use of personalized medicines and diagnostics is considered depending on a patient's specific attributes. Methods of treatments such as hyperthermia and radiotherapy have already been proposed. Further, the report states that one of the main challenges is low awareness about personalized medicine diagnostics in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in personalized medicine diagnostics. The high cost of personalized medicine diagnostics in certain treatments is another major challenge for the market in these countries. Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Becton Dickinson and Company - bioMerieux SA - Illumina Inc. - Roche Holding AG. - 20/20 GeneSystems Inc. - Accumetrics Inc. - AdvanDx Inc. - Affymetrix Inc. - Almac Group Ltd. - AltheaDx Inc. - Ambry Genetics Corp. - Amgen Inc. - Arrayit Corp. - AssureRx Health Inc. - Autogenomics Inc. - BG Medicine Inc. - Biocare Medical LLC - Biocartis SA - Biocept Inc. - BioCurex Inc. - Biodesix Inc. - Bio-Reference Laboratories Inc. - CombiMatrix Corp. - Corgenix Medical Corp. - DxTerity Diagnostics Inc. - EnzoBiochem Inc. - Epigenomics AG - Euroimmun AG - GE Healthcare - Genomic Health Inc. - Interleukin Genetics Inc. - Johnson & Johnson - Knome Inc. - Lab21 Ltd. - Life Technologies Corp. - MDxHealth SA - Myriad Genetics Inc. - Nanosphere Inc. - Pathway Genomics Corp. - Power3 Medical Products Inc. - Quest Diagnostics Inc. - Response Genetics Inc. - Rosetta Genomics Ltd. - Sequenom Inc. - Trovagene Inc. - Vermillion Inc. - Viracor-IBT Laboratories Inc. For more information visit http://www.researchandmarkets.com/research/x63hs3/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Corgenix Medical Corporation will participate at Houston's AACC Clinical Lab Expo 2013 from 30 July to 1 August
M2 - Thu Jul 18, 9:30AM CDT
Diagnostic test kits supplier Corgenix Medical Corporation (OTC Markets:CONX) said on Wednesday that it has entered into a collaboration to display its AspirinWorks (11dhTxB2) Test at the AACC Clinical Lab Expo 2013 in Houston, Texas.
Corgenix Rapid Diagnostic Ebola Test Research Earns Divisional Best Abstract Award at AACC 2014 Meeting
Business Wire - Wed Jul 30, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX) has been recognized for outstanding research presented today at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago. Corgenix earned the award for its poster abstract "Development of a Point-of-Care Diagnostic for Ebola and Sudan Virus Detection," presented at the conference by Corgenix Research Associate Abby Jones, M.S.
Corgenix Joins Strategic Partners, Presents Science at AACC Meeting and Clinical Lab Expo 2014
Business Wire - Tue Jul 22, 8:15AM CDT
Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, will collaborate with strategic partners and also present several scientific abstracts at the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Expo 2014 in Chicago.
Corgenix enters into technology transfer & product development agreement for Mellitussfor gestational diabetes test GCD59
M2 - Tue Jul 15, 8:29AM CDT
Diagnostic test kits company Corgenix Medical (Other OTC:CONX) on Monday launched a technology transfer and product development agreement with Mellitus in support of clinical research and product commercialisation.
Corgenix Signs Technology Transfer, Product Development Agreement with Mellitus LLC for Gestational Diabetes Test
Business Wire - Mon Jul 14, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, today announced a technology transfer and product development agreement with Mellitus LLC of Cambridge, Mass. Mellitus is a private company that is developing a novel in vitro diagnostic test with potential clinical utility for diabetes. The test is based on the measurement of Glycated CD59 (GCD59.)
Corgenix, Research Group Announce NIH Grant to Advance Work on Ebola Rapid Diagnostic Test Kit
Business Wire - Thu Jun 26, 8:15AM CDT
Corgenix Medical Corporation (OTC BB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, has been awarded a three-year, $2.9 million National Institutes of Health (NIH) grant to advance the development of an Ebola rapid diagnostic test kit. Collaborating with Corgenix on the program will be members of the Viral Hemorrhagic Fever Consortium (VHFC), a collaboration of academic and industry members headed by Tulane University and partially funded with support from the NIH.
Corgenix, Tulane and Viral Hemorrhagic Fever Consortium Publish Promising Results from Lassa Fever Trial
Business Wire - Tue Apr 01, 8:15AM CDT
A Corgenix Medical (OTCBB:CONX) rapid diagnostic test (RDT) for the dangerous Lassa fever virus has demonstrated the ability to quickly detect the virus, responsible for the deaths of thousands and infection of hundreds of thousands in West Africa each year. That's according to the results of the five-year trial Lassa Fever in Post-Conflict Sierra Leone published in the PLOS Neglected Tropical Diseases Journal.
Corgenix and Research Partners to Expand Ebola Virus Testing Capabilities in Sierra Leone
Business Wire - Thu Mar 27, 8:15AM CDT
An outbreak of the deadly Ebola virus in West Africa has prompted Corgenix Medical Corporation (OTCBB:CONX) to extend its existing viral hemorrhagic fever (VHF) rapid test development to include the Ebola virus. Corgenix has already developed and CE marked a rapid test for the Lassa fever virus, another member of the VHF group of viruses.
Corgenix Board of Directors Announces Exploration of Strategic Alternatives
Business Wire - Wed Mar 12, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that the Company's Board of Directors has decided to explore strategic alternatives to enhance value for shareholders. These alternatives could include, among others, possible joint ventures, strategic partnerships or alliances, a sale of the Company or other possible transactions.
Corgenix Medical Corporation posts higher net income of USD178,497 for Q2 fiscal 2014
M2 - Fri Feb 14, 3:06AM CST
Diagnostic test kits company Corgenix Medical Corporation (OTC BB:CONX) reported on Thursday its net income of USD178,497 for second quarter fiscal 2014.
Corgenix Reports Second Quarter Fiscal 2014 Financial Results
Business Wire - Thu Feb 13, 8:15AM CST
Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its second quarter Form 10-Q and reported its financial results. The report disclosed that the company's revenues and net income increased both for the quarter and year to date. Some of the results highlighted by the report are as follows:
Corgenix to Host Conference Call to Discuss Second Quarter Results
Business Wire - Tue Feb 04, 8:15AM CST
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, February 13, 2014, at 4:00 p.m. EST to discuss the Company's financial and operating performance for its quarter ended December 31, 2013, and the status of the Company's product development and marketing activities.
Corgenix Announces Filing of 510(k) Premarket Notification for FDA Clearance of TxBCardio(TM) Assay
Business Wire - Mon Dec 16, 8:15AM CST
Corgenix Medical Corporation (OTC BB: CONX.OB) announced today that in collaboration with Randox Laboratories, the first premarket notification has been filed with the U.S. Food and Drug Administration pursuant to Section 510(k) of the U.S. Federal Food, Drug and Cosmetic Act for the TxBCardio(TM) immunoturbidimetric (IT) assay.
Corgenix to Host Conference Call to Discuss Fiscal 2013 Results
Business Wire - Wed Sep 18, 8:15AM CDT
Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Monday, September 30, 2013, at 4:00 PM EDT to discuss the Company's financial and operating performance for its fiscal year ended June 30, 2013, and the status of the Company's product development and marketing activities.
Corgenix Medical Corporation renews agreement with Dr Matsuura and retains right to the AtherOx technology
M2 - Wed Sep 11, 9:38AM CDT
Diagnostic kits company Corgenix Medical Corporation (OTCQB:CONX.OB) reported on Tuesday the execution of a new AtherOx License and Cooperation Agreement with Dr Eiji Matsuura of Okayama, Japan.
Corgenix Medical Corporation Announces New AtherOx(R) (Oxidized LDL Technology) License and Cooperation Agreement
Business Wire - Tue Sep 10, 8:15AM CDT
Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced signing of a new AtherOx(R) License and Cooperation Agreement with Eiji Matsuura, Ph.D., an individual of Okayama, Japan. Concurrently with the execution of the new agreement, Dr. Matsuura terminated his arbitration demand of June 28, 2013 related to the April 14, 2010 Amended and Restated License Agreement between the parties.
Corgenix Medical Corporation reports new USD1.5m revolving credit facility, with favorable interest rate and greater flexibility
M2 - Thu Sep 05, 6:29AM CDT
Diagnostic test kits company Corgenix Medical Corporation (OTCQB:CONX.OB) revealed on Wednesday the completion of a USD1.5m secured revolving line of credit with Bank of the West.
Corgenix Medical Corporation Announces New $1.5 Million Revolving Credit Facility
Business Wire - Wed Sep 04, 8:15AM CDT
Corgenix Medical Corporation (OTCQB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced that it has closed on a $1.5 million secured revolving line of credit with Bank of the West. The new revolving line of credit provides Corgenix a very favorable interest rate and much greater flexibility than the previous asset-based revolving line of credit. The new credit facility follows the recent move by Corgenix of its primary banking arrangements to Bank of the West.
OTC Daily Alert Stock Watch - Corgenix (OTCQB: CONX)
WorldStockWire - Tue Aug 27, 7:15PM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Global Personalized Medicine Diagnostics Market 2012-2016: AltheaDx Inc. Launches FLT3 Mutation Assay in October 2012
M2 - Tue Aug 06, 12:26PM CDT
Research and Markets (http://www.researchandmarkets.com/research/x63hs3/global) has announced the addition of the "Global Personalized Medicine Diagnostics Market 2012-2016" report to their offering. The analysts forecast the Global Personalized Medicine Diagnostics market to grow at a CAGR of 4.43 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing demand for personalized medicine for treating cancer. The Global Personalized Medicine Diagnostics market has also been witnessing an increase in the number of industrial activities. However, the low awareness of personalized medicine diagnostics in developing countries could pose a challenge to the growth of this market. The key vendors dominating this space include Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Company, bioMerieux SA, Illumina Inc., and Roche Holding AG. Commenting on the report, an analyst from the team said: One of the main trends witnessed in the Global Personalized Medicine Diagnostics market is the development of innovative tools and technologies. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Furthermore, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 to predict the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011. According to the report, one of the main factors driving the market is the increasing demand for personalized medicine diagnostics for treatment of cancer. Hyperthermia is one of the treatments of cancer where the use of personalized medicines and diagnostics is considered depending on a patient's specific attributes. Methods of treatments such as hyperthermia and radiotherapy have already been proposed. Further, the report states that one of the main challenges is low awareness about personalized medicine diagnostics in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in personalized medicine diagnostics. The high cost of personalized medicine diagnostics in certain treatments is another major challenge for the market in these countries. Companies Mentioned: - Abbott Laboratories - Agilent Technologies Inc. - Becton Dickinson and Company - bioMerieux SA - Illumina Inc. - Roche Holding AG. - 20/20 GeneSystems Inc. - Accumetrics Inc. - AdvanDx Inc. - Affymetrix Inc. - Almac Group Ltd. - AltheaDx Inc. - Ambry Genetics Corp. - Amgen Inc. - Arrayit Corp. - AssureRx Health Inc. - Autogenomics Inc. - BG Medicine Inc. - Biocare Medical LLC - Biocartis SA - Biocept Inc. - BioCurex Inc. - Biodesix Inc. - Bio-Reference Laboratories Inc. - CombiMatrix Corp. - Corgenix Medical Corp. - DxTerity Diagnostics Inc. - EnzoBiochem Inc. - Epigenomics AG - Euroimmun AG - GE Healthcare - Genomic Health Inc. - Interleukin Genetics Inc. - Johnson & Johnson - Knome Inc. - Lab21 Ltd. - Life Technologies Corp. - MDxHealth SA - Myriad Genetics Inc. - Nanosphere Inc. - Pathway Genomics Corp. - Power3 Medical Products Inc. - Quest Diagnostics Inc. - Response Genetics Inc. - Rosetta Genomics Ltd. - Sequenom Inc. - Trovagene Inc. - Vermillion Inc. - Viracor-IBT Laboratories Inc. For more information visit http://www.researchandmarkets.com/research/x63hs3/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Corgenix Medical Corporation will participate at Houston's AACC Clinical Lab Expo 2013 from 30 July to 1 August
M2 - Thu Jul 18, 9:30AM CDT
Diagnostic test kits supplier Corgenix Medical Corporation (OTC Markets:CONX) said on Wednesday that it has entered into a collaboration to display its AspirinWorks (11dhTxB2) Test at the AACC Clinical Lab Expo 2013 in Houston, Texas.
